Taxanes – The backbone of medical oncology
Drug development in oncology has witnessed a revolutionary growth from its humble beginning with nitrogen mustard in 1940 to immunotherapy in 1986 (Interferon alpha). The arsenal of cytotoxics is ever increasing, contributing to better survival outcomes and improved quality of life. Over the years,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=221;epage=234;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850226806250012672 |
|---|---|
| author | Wesley M Jose |
| author_facet | Wesley M Jose |
| author_sort | Wesley M Jose |
| collection | DOAJ |
| description | Drug development in oncology has witnessed a revolutionary growth from its humble beginning with nitrogen mustard in 1940 to immunotherapy in 1986 (Interferon alpha). The arsenal of cytotoxics is ever increasing, contributing to better survival outcomes and improved quality of life. Over the years, many cytotoxics have fallen out of favor too, due to its side effects and availability of drugs with better efficacy and toxicity profile. Taxane, a microtubule stabilizing agent extracted from the poisonous Yew tree, was discovered in 1964 and came into clinical use in 1992 with its approval for ovarian cancer. This group has grown into a cornerstone of many treatment protocols, spanning multiple tumor types. This review discusses in brief the salient features of cytotoxic agents in this drug group, its history, physico-chemical properties, mechanism of action, pharmacodynamics, and pharmacokinetics. Though the benefits of taxanes are well understood, there are unique problems associated with the use of taxanes and there is an expanding literature on taxane resistance. We briefly look at the resistance mechanisms. There have been significant efforts to circumvent the problems related to conventional taxanes, with an attempt at creating newer carrier molecules and adjunct drugs with taxanes, which is slowly gaining traction in clinical practice. |
| format | Article |
| id | doaj-art-efcaf8a1727c48e9a2ce58a8c06be28d |
| institution | OA Journals |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-efcaf8a1727c48e9a2ce58a8c06be28d2025-08-20T02:04:58ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292020-01-0141222123410.4103/ijmpo.ijmpo_1_20Taxanes – The backbone of medical oncologyWesley M JoseDrug development in oncology has witnessed a revolutionary growth from its humble beginning with nitrogen mustard in 1940 to immunotherapy in 1986 (Interferon alpha). The arsenal of cytotoxics is ever increasing, contributing to better survival outcomes and improved quality of life. Over the years, many cytotoxics have fallen out of favor too, due to its side effects and availability of drugs with better efficacy and toxicity profile. Taxane, a microtubule stabilizing agent extracted from the poisonous Yew tree, was discovered in 1964 and came into clinical use in 1992 with its approval for ovarian cancer. This group has grown into a cornerstone of many treatment protocols, spanning multiple tumor types. This review discusses in brief the salient features of cytotoxic agents in this drug group, its history, physico-chemical properties, mechanism of action, pharmacodynamics, and pharmacokinetics. Though the benefits of taxanes are well understood, there are unique problems associated with the use of taxanes and there is an expanding literature on taxane resistance. We briefly look at the resistance mechanisms. There have been significant efforts to circumvent the problems related to conventional taxanes, with an attempt at creating newer carrier molecules and adjunct drugs with taxanes, which is slowly gaining traction in clinical practice.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=221;epage=234;aulast=cabazitaxelcremophordiethylhexyl phthalatedocetaxelpaclitaxeltoxicity |
| spellingShingle | Wesley M Jose Taxanes – The backbone of medical oncology Indian Journal of Medical and Paediatric Oncology cabazitaxel cremophor diethylhexyl phthalate docetaxel paclitaxel toxicity |
| title | Taxanes – The backbone of medical oncology |
| title_full | Taxanes – The backbone of medical oncology |
| title_fullStr | Taxanes – The backbone of medical oncology |
| title_full_unstemmed | Taxanes – The backbone of medical oncology |
| title_short | Taxanes – The backbone of medical oncology |
| title_sort | taxanes the backbone of medical oncology |
| topic | cabazitaxel cremophor diethylhexyl phthalate docetaxel paclitaxel toxicity |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=221;epage=234;aulast= |
| work_keys_str_mv | AT wesleymjose taxanesthebackboneofmedicaloncology |